With regard to Aboriginal Affairs and Northern Development Canada and Health Canada, breaking down each response by First Nations or Inuit community: (a) what was the number of registered First Nations or Inuit clients with a prescription for OxyContin under the Non-Insured Health Benefit (NIHB) Program in each of the years from 2006 to 2012 inclusive; (b) how many requests for Suboxone treatment were received by NIHB after it was listed on December 7, 2011, and, of these (i) how many were granted, (ii) what was the reason given for requests that were refused, (iii) was an alternative treatment offered to those clients whose requests were refused, (iv) what measures were taken to measure the health outcomes of clients whose requests were refused; (c) is there a doctor, nurse or other health professional trained in drug treatment in the community; (d) is there a healing centre in the community, and, if not, what is the location of the closest or most-readily accessible healing centre; (e) what sort of culturally-appropriate psychosocial aftercare services are available in the community for clients who have completed a detoxification program; (f) did the government conduct evaluations of the level of substance abuse during the period 2006 to 2012, and, if so, (i) how has the rate changed over time, (ii) what is the extent of abuse of legally-obtained prescription drugs, (iii) what is the extent of abuse of illegally-obtained prescription drugs; (g) what was the amount of funding for drug prevention and drug treatment in each of the years from 2006 to 2012 inclusive, and what was the amount of funding dedicated specifically to prescription drug abuse, obtained both legally and illegally; and (h) what was the amount of funding for the National Native Alcohol and Drug Abuse Program in each of the years from 2006 to 2012 inclusive, and what was the amount spent on (i) prevention activities, (ii) intervention activities, (iii) aftercare activities?
In the House of Commons on April 23rd, 2012. See this statement in context.